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Background: Patients with ischemic cardiomyopathy (ICM) are at an increased risk for sudden death.
Although earlier trials used programmed electrical stimulation (PES) for risk stratiﬁcation, more recent
data demonstrate the beneﬁt of implantable cardiac deﬁbrillators (ICDs) in selected patients with
reduced left ventricular ejection fraction (LVEF) without performing PES. However, little is known about
the outcome of non-inducible patients. The purpose of this study was to evaluate the efﬁcacy of PES for
mortality risk stratiﬁcation in patients with ICM.
Methods: All consecutive patients who met the inclusion criteria (history of coronary artery disease,
LVEFr35%, and absence of documented spontaneous sustained ventricular tachycardia or aborted
sudden cardiac death) were included in the study. The stimulation protocol involved up to three
extrastimuli from two different sites in the right ventricle, with 180 ms as the shortest coupling interval.
The primary endpoint was overall survival.
Results: A total of 198 patients were included in the study; of these, 60 exhibited negative ()PES, and 138 had
positive (þ)PES and also underwent ICD implantation. The mean follow-up duration was 4.5 years. There was
no difference in age or LVEF between the patient groups. We found a trend towards an increased 5-year survival
rate in the (þ)PES group in whom ICD implantation had been performed (p¼0.058). Survival was signiﬁcantly
better in patients under 68 year olds in the (þ)PES group in whom ICD implantation was performed (hazard
ratio¼0.3, p¼0.01). The survival rate of patients Z68 years old was similar in both groups (p¼0.95).
Conclusions: Non-inducibility during PES does not predict the prognosis of patients with ischemic cardiomyo-
pathy.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Patients with ischemic cardiomyopathy are at an increased risk for
serious ventricular arrhythmias and sudden cardiac death (SCD).
Epidemiological studies indicate that more than 50% of cardiac deaths
are sudden [1,2]. Antiarrhythmic drugs (AAD) do not reduce mortality
in these patients [3–7]. Although earlier trials used programmed
electrical stimulation (PES) for risk stratiﬁcation [6–8], more recent
data demonstrate the beneﬁt of implantable cardiac deﬁbrillators
(ICDs) to treat patients with severely reduced left ventricular ejection
fractions (LVEF) without performing PES [7,9]. However, as many
patients will never have any ICD treatment, further risk stratiﬁcation is
required. The MADIT I and II studies included PES before randomiza-
tion to ICD or medical therapy (PES was not mandatory but
encouraged in MADIT II and was performed in 80% of the patients).
In the MUSTT study, a registry of all patients recruited was maintained,
and included those patients who did not experience abnormal
rhythms induced during PES (non-inducible patients). Buxton et al.
showed that with no antiarrhythmic therapy, the non-inducible
patients had better prognosis than inducible patients [10]. However,
the mortality rate of both groups was still high, and the non-inducible
patients might still beneﬁt from ICD. The purpose of this study was to
evaluate the efﬁcacy of PES for risk stratiﬁcation based onmortality for
inducible patients treated with ICD vs. non-inducible patients in a
“real-world” registry.
2. Materials and methods
2.1. Study cohort
We performed a retrospective analysis of all consecutive
patients referred for PES between 1999 and 2009, who met the
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following inclusion criteria: 1. Presence of coronary artery disease
(CAD); 2. time from the last myocardial infarction to PES440
days; and 3. LVEFr35%. Patients with documented sustained
ventricular arrhythmias were excluded. During this period, criteria
for ICD implantation in Israel for primary prevention were similar
to those of the MADIT I study; hence, this was the common
practice. Since 2009, MADIT II inclusion criteria have been gradu-
ally implemented. Patients enrolled at that time had LVEFs 31–35%
and therefore needed to have positive PES to be eligible for an ICD.
The study protocol was approved by the institutional review board
of Carmel Medical Center (IRB protocol no. 0126-09-CMC; date of
approval July 7th, 2010).
2.2. Deﬁnitions
The presence of CAD was determined based on a history of
myocardial infarction. We included data regarding medications at
the time of hospital discharge after the procedure. Mitral regur-
gitation (MR) grade (0 – normal, 3 – severe) was determined using
echocardiography.
2.3. Electrophysiological study
The protocol included stimulation from two right ventricular
sites (the apex and septum) and two different drive trains (600 ms
and 400 ms) [6]. We used up to three extrastimuli, with the
shortest coupling interval being 180 ms. No drug was adminis-
tered to enhance inducibility. Induction of sustained (Z30 s) or
unstable VT, or ventricular ﬂutter (VFL), was considered positive
PES, while induction of ventricular arrhythmias other than mono-
morphic VT was considered positive only if reproducibly induced
with a single or double extra-stimuli. Monomorphic VT was
deﬁned as a VT with a uniform stable QRS morphology with a
cycle length4230 ms. VFL was deﬁned as sustained mono-
morphic VT with a shorter cycle length (r230 ms). Ventricular
ﬁbrillation (VF) was deﬁned as a rapid disorganized rhythm
without consistently identiﬁable complexes.
2.4. Device implantation
All patients with (þ)PES underwent ICD implantation within
the same week. The implantation and programming were not
uniform but left to the discretion of the operator. However,
programming was typically performed according to the PainFREE
Rx II study protocol. Patients underwent dual-chamber ICD
implantation if they had a history of atrial arrhythmias.
2.5. Patient follow-up
For patients who underwent ICD implantation, follow-up was
conducted at our ICD clinic 3–6 months interval. Appropriate ICD
therapy was deﬁned as any therapy (anti-tachycardia pacing or DC
shock) given for sustained ventricular arrhythmia. Inappropriate
therapy was deﬁned as therapy administered for supraventricular
tachycardia. Survival status, record of hospitalization, and medical
events were veriﬁed using the Health Maintenance Organization
(HMO) database. Follow-up for all other patients utilized the HMO
database.
2.6. Study endpoints
The primary study endpoint was overall survival. In addition,
we evaluated complications related to the ICD implantation, such
as infection, lead reposition, deep venous thrombosis, and inap-
propriate activation.
2.7. Statistical analysis
Analysis was performed according to an intention-to-treat
model. Continuous variables were compared using Student's t-test
or the Mann–Whitney U test, as appropriate. Continuous variables
with a non-normal distribution are presented as median (inter-
quartile range). Categorical variables are expressed as percentages
and were compared using Chi-squared or Fisher's exact tests, as
appropriate. Univariate and multivariate Cox proportional hazards
models for survival with a stepwise procedure were performed.
Hazards ratios with 95% conﬁdence intervals were estimated from
Table 1
Baseline characteristics.
Inducible Non-inducible p Value
Number 138 60
Age (years) 66.379 68.578.6 0.14
Females, n (%) 51 (45.1) 29 (51.8) 0.41
Mean follow-up (months), mean7SD 42.0719.0 43.3718.7 0.64
LVEF, % 27.775.6 2874.7 0.65
LVEDD, mm 59.376.9 58.276.8 0.3
Mitral regurgitation (0–4 scale), mean7SD 1.0370.8 1.170.9 0.45
Previous PCI, n (%) 63 (46) 28 (47) 0.9
Previous CABG, n (%) 68 (49) 45 (27) 0.58
Mean time from previous MI or revascularization (years)7SD 876 8.175.9 0.88
Atrial ﬁbrillation, n (%) 21 (15.2) 17 (28.8) 0.027
Diabetes, n (%) 30 (50) 50 (36.2) 0.07
Hypertension, n (%) 81 (58.7) 40 (66.7) 0.29
Creatinine (mg/dL), mean7SD 1.270.5 1.270.46 0.98
Medications
β-Blockers, n (%) 136 (98.6) 52 (86.7) o0.001
ACE inhibitors, n (%) 125 (90.6) 56 (93.3) 0.53
Amiodarone, n (%) 12 (8.7) 7 (11.7) 0.51
Other antiarrhythmic drugs, n (%) 13 (9.4) 6 (10) 0.9
Aldospirone, n (%) 19 (14) 12 (20) 0.27
Digoxin, n (%) 17 (12.3) 12 (20) 0.16
LVEF, left-ventricular ejection fraction; LVEDD, left-ventricular end diastolic diameter; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MI,
myocardial infarction.
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the models. All tests were two-sided with a signiﬁcance level of
0.05. Statistical analyses were performed using SPSS software
(SPSS Inc., version 16th, Chicago, Illinois).
3. Results
A total of 198 patients were included in the study. Of these, 138
exhibited (þ)PES and underwent ICD implantation and 60 exhib-
ited ()PES and were followed clinically. The mean follow-up
period was 44.2717.6 months. The baseline characteristics upon
inclusion into the study are presented in Table 1. The mean age of
the ()PES patients was similar to that of the (þ)PES group
(68.578.6 and 66.379 years, respectively; p¼0.14). The mean
LVEF of all patients was 27.875.3% and did not differ between the
two groups. More patients in the ()PES group had a history of
atrial ﬁbrillation (28.8% vs. 15.2%, p¼0.027). β-Blockers were used
less often in the ()PES group (86.7% vs. 98.6%, po0.001). Base-
line electrocardiographic characteristics were similar in the two
groups. Some characteristics of ECG and PES are presented in
Table 3.
The primary outcome, ﬁve-year survival rate, showed a trend
towards increased survival in the (þ)PES group in which ICD
implantation was performed compared to the ()PES group (20%
vs.. 35%, p¼0.058) (Fig. 1A, Table 2). Survival rates signiﬁcantly
reduced in younger patients (r68 years old) who did not undergo
ICD implantation (HR, hazard ratio¼0.3; Fig. 1B), especially in
young patients with severely reduced LVEF (r25%) (HR¼0.1;
Table 2). Of note, the cut-off of 68 years old was chosen for
subgroup analysis because it was the median age in the study.
In the univariate subgroup analysis, the factors that predicted
reduced survival were increased age, signiﬁcant mitral regurgita-
tion (Z grade 2), and creatinine level (Table 4). After multivariate
analysis, (þ)PES followed by ICD implantation was a strong
predictor of reduced mortality, along with creatinine level and
MR grade (Table 5).
Ten (16.7%) patients in the ()PES group underwent “cross-
over” ICD implantation during the mean follow-up period of
38719 months. Of these, three underwent repeat (þ)PES at an
average of 44715 months after the ﬁrst PES and did not
experience any arrhythmic symptoms; two received a pacemaker
or underwent internal loop recorder documentation of non-
sustained VT; three developed an indication for CRT implantation;
and in two patients, a change in the HMO policy enabled ICD
implantation despite the PES result. None of the patients experi-
enced cross-over owing to symptomatic arrhythmia.
4. Discussion
The main ﬁndings of our study are that patients with inducible
VT during PES and underwent ICD implantation exhibited a trend
towards improved survival compared to patients with non-
inducible PES. Therefore, PES cannot reliably predict mortality in
the general population of patients with ischemic cardiomyopathy.
Fig. 1. Kaplan–Meier estimates of survival. (A) A trend towards a higher survival rate in the positive programmed electrical stimulation [(þ)PES] group is apparent.
(B) Subgroup analysis according to age, showing patients younger than 68 years. Patients with (þ)PES who underwent implantable cardiac deﬁbrillator (ICD) implantation
experienced improved survival compared to patients in the negative ()PES group. C. Among patients Z68 years of age, there was no difference in mortality rates between
the groups (p¼0.97).
Table 2
Clinical outcomes.
Inducible Non-inducible HR 95% CI p Value
Five-year mortality, n (%) 27 (20) 21 (35) 0.58 0.33, 1.02 0.058
Five-year mortality in patientsr68 years
All, no. of events (%) 8 (11) 10 (35) 0.3 0.12, 0.76 0.007
LVEFr25% 3 (9) 6 (60) 0.1 0.03, 0.42 0.001
LVEF425% 5 (12) 4 (21) 0.69 0.18, 2.57 0.58
Five-year mortality in patients468 years
All, no. of events (%) 19 (30) 11 (36) 0.97 0.46, 2.05 0.95
LVEFr25% 10 (40) 5 (38) 0.89 0.3, 2.6 0.83
LVEF425% 9 (24) 6 (33) 1.08 0.38, 3.05 0.89
HR, hazard ratio; LVEF, left ventricular ejection fraction.
Table 3
Electrophysiological characteristics.
Inducible Non-inducible p Value
ECG analysis
QRS duration, ms7SD 128731 130727 0.65
PR duration, ms7SD 201747 205742 0.66
QTc duration, ms7SD 0.4670.05 0.4570.08 0.76
fQRS duration (%) 59 (66.3) 30 (63.8) 0.77
Number of extra-stimuli (n)7SD 2.670.5 2.770.5 0.12
Shortest coupling interval (ms)7SD 216727 199717 o0.001
Induction of ventricular arrhythmia
None 0 (0) 52 (87)
Ventricular tachycardia 119 (86) 0 (0)
Ventricular ﬂutter 19 (14) 2 (3)
Polymorphic VT 0 (0) 2 (3)
Ventricular ﬁbrillation 0 (0) 4 (7)
QTc, QT corrected according to Bazett formula; fQRS, fragmented QRS; VT,
ventricular tachycardia.
A. Danon et al. / Journal of Arrhythmia 31 (2015) 147–151 149
Interestingly, subgroup analysis according to age showed poor
survival among non-inducible patientso68 years old (the median
age in the study) who did not undergo ICD implantation compared
to patients who underwent ICD implantation, especially in those
with severely reduced LVEF (r25%) (Table 2 and Fig. 1B). On the
other hand, survival of elderly patients (468 years old) was
similar in both groups.
Several large studies evaluated the effectiveness of PES for the
risk stratiﬁcation of patients with CAD who have moderately to
severely reduced LVEF. The MUSTT study compared EP-guided
therapy vs. conventional therapy in inducible patients with CAD
and reduced LVEF, and found that ICD implantation, but not AAD,
reduced the risk of sudden death in inducible patients [6].
In addition to the main MUSTT trial, the non-inducible patients
were included in a registry. The mortality rate of the non-inducible
patients was signiﬁcantly lower than that of the inducible patients
receiving non-EP-guided therapy [10], but this rate was still high
(21% in two years). Treatment with β-blockers was prescribed to
less than half of the patients. The authors of the MUSTT trial
concluded that non-inducibility during PES is a good predictor for
improved survival [11]. The MADIT I study examined the effec-
tiveness of ICD on mortality rate in CAD patients with LVEFr35%,
with inducible but not suppressible VT during PES [8]. However,
the outcome of non-inducible patients in this study is not known.
β-Blockers were administered to less than 10% of the patients. In
the MADIT II trial, patients with CAD and severely reduced LVEF
(r30%) were randomized to ICD implantation or conventional
therapy without requiring PES [9]. Nonetheless, PES was encour-
aged by the study committee, and 82% of the patients in the ICD
arm underwent PES [12]. In the subgroup analysis, appropriate ICD
therapy was more common in the inducible patients, but was still
high in the non-inducible group (25.5% at two years). However,
appropriate ICD therapy for ventricular arrhythmia occurs more
frequently than death among those patients and therefore cannot
be used as a surrogate for mortality. Furthermore, β-blockers and
angiotensin-converting-enzyme inhibitors were administered to
approximately 70% of the patients. Thus, we lack updated data
regarding the outcome of non-inducible patients who were
treated based on current guidelines and recommendations, includ-
ing the use of β-blockers. Recently, Zaman et al. showed that PES is
a strong predictor of mortality early after acute MI [13].
Current guidelines recommend ICD for patients with EFr35%
and New York Heart Association (NYHA) class II or III status,
without the need to induce VT during PES. This recommendation
is based on the large trials mentioned above. However, MADIT II
included patients with EFr30%. Although the SCD-Heft study [7]
recruited patients with EFr35%, the subgroup with EF430% was
small (285 patients) and subgroup analysis failed to demonstrate a
survival beneﬁt with ICD in this group. In the MUSTT study,
patients underwent PES for risk stratiﬁcation. However, the
MUSTT study excluded non-inducible patients while the MUSTT
registry compared only between non-inducible patients to indu-
cible patients whom did not underwent ICD implantation. Thus,
our study provides information that supports the current guide-
lines and recommendations for ICD implantation for the primary
prevention of ventricular arrhythmias without using PES for risk
stratiﬁcation. Because device implantation carries a substantial
cost and potential for complications, further risk stratiﬁcation is
needed [14]. Thus far, many predictors of SCD risk have been
identiﬁed, including age [15], renal function, degree of LV dysfunc-
tion, and electrocardiographic parameters such as QRS duration
and notching [14]. However, none of these parameters could
clearly inﬂuence the guidelines and recommendations owing to
the lack of speciﬁcity. Subgroup analysis of our results shows that
in elderly patients, the survival rate was similar in both groups,
despite the lack of ICD implantation in the ()PES group (Table 2
and Fig. 1C). Mortality causes in this group may be different, and
thus, the ICD beneﬁt may reduce [16]. In contrast, younger patients
(r68 years old) who did not undergo ICD implantation had a
signiﬁcantly lower survival rate despite showing ()PES, with a
hazard ratio of 0.3. However, this ﬁnding should be conﬁrmed in
larger patient populations, as the current study was underpow-
ered for this type of analysis.
Our two groups of patients were similar in all, but two,
parameters: the non-inducible group had a signiﬁcantly higher
prevalence of atrial ﬁbrillation (Table 1) and a signiﬁcantly lower
use of β-blockers at the time of enrollment into the study
(discharge time after PES only or ICD implantation). The latter
difference may be related to the lack of back-up pacing, because
some these patients had bradycardia.
5. Study limitations
We performed an intention-to-treat statistical analysis includ-
ing patients in the ()PES group analysis who underwent ICD
implantation (“crossover”). Although this type of analysis may
result in overestimation of the survival rate in the ()PES group,
the odds are low owing to the relatively long interval between
enrollment and crossover. Furthermore, crossover is common in
many ICD trials, and intention-to-treat is still the preferred
method of analysis. The follow-up of our registry did not include
documentation of repeated ischemic events and repeated LV
function assessments, which could deteriorate or improve over
time and have an effect on patient outcome. However, neither of
the large studies discussed above included such data. We used
total mortality rates as an end-point and did not have information
about the cause of death. Therefore, non-cardiac causes of death
may have inﬂuenced our results. However, most trials involving
ICD implantation used all-cause mortality as the primary end-
point. In addition, non-arrhythmic causes of death may also
inﬂuence the beneﬁt of ICD in clinical practice. Finally, we
performed a subanalysis according to age, which suggested that
elderly patients may have similar survival for both (þ)PES with
ICD implantation and ()PES. The study was underpowered for
such an analysis, but we chose to describe it because the results
Table 4
Univariate analysis of ﬁve-year mortality rates.
Variable HR 95% CI p Value
(þ) PES 0.58 0.33–1.03 0.06
Age468 years 2.15 1.2–3.8 0.01
LVEFZ25% 0.78 0.4–1.4 0.38
Mitral regurgitationZgrade 2 2.8 1.5–5.1 0.01
Creatinine level 2.1 1.5–2.8 o0.0001
PES, programmed electrical stimulation; LVEF, left ventricular ejection fraction;
HR, hazard ratio.
Table 5
Multivariate analysis of ﬁve-year mortality rate.
Variable HR 95% CI p value
(þ) PES 0.29 0.1–0.83 0.02
AGE468 years 1.24 0.45–3.46 0.68
LVEFZ25% 0.67 0.36–1.25 0.21
Mitral regurgitationZgrade 2 4.44 2.26–8.71 o0.0001
Creatinine 2.43 1.65–3.57 o0.0001
PES, programmed electrical stimulation; HR, hazard ratio.
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were signiﬁcant and are supported by the results of previous
studies (15).
In conclusion, ()PES cannot be used for risk stratiﬁcation in
the general population with ischemic cardiomyopathy. However,
future studies should evaluate the role of PES in the elderly and in
patients with less severe LV dysfunction (LVEF430%), to improve
the cost-effectiveness of ICD.
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